Extraintestinal manifestations are frequent in inflammatory bowel diseases (IBD).
Most studies published so far focused on viral hepatitis and liver toxicity of IBD-related drugs.
Professor Peyrin-Biroulet and colleagues from France conducted a systematic review of hepatobiliary manifestations associated with IBD.
The researchers excluded viral hepatitis and liver toxicity of IBD-related drugs.
Studies were identified through the electronic database of MEDLINE, EMBASE and the annual meetings of Digestive Disease Week, the American College of Gastroenterology, the United European Gastroenterology Week and the European Crohn's and Colitis Organization.
The team included 146 articles in this systematic review.
The mean prevalence of fatty liver is 23%
|Alimentary Pharmacology & Therapeutics|
Cholelithiasis is more frequent in Crohn's disease than in general population.
The team found that the prevalence of cholelithiasis in Crohn's disease ranged from 11% to 34%, whereas it ranges from 6% to 15% in non-IBD patients.
PSC is more frequent in ulcerative colitis than in Crohn's disease.
Prevalence of PSC ranges from 0.8% to 5% in ulcerative colitis, and from 1% to 3% in Crohn's disease.
The team observed a male predominance when PSC is associated with ulcerative colitis, with a male/female ratio ranging from 65/35 to 70/30.
No conclusion can be made on a possible increased risk of gall-bladder carcinoma.
The research team found that the mean prevalence of fatty liver is 23%.
Hepatic amyloidosis occurs in less than 1% of IBD.
Liver abscess is encountered mainly in Crohn's disease.
The team noted that portal vein thrombosis occurs in 39% to 45% of IBD patients undergoing proctocolectomy.
Professor Peyrin-Biroulet's team comments, "Hepatobiliary manifestations associated with inflammatory bowel diseases are frequent and probably underdiagnosed."